However, the potential loss of physiological effect of NLRP3 on vascular maintenance in the relatively healthy brain region should be considered as a side-effect in future translational studies of NLRP3 inhibitors in AD patients (Quan et al., 2020). The gene discussed is NLRP3; the disease is Alzheimer disease.